Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Endo Health Solutions Inc    ENDP

News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Endo Health Solutions Inc : Endo Completes Acquisition of Paladin Labs

share with twitter share with LinkedIn share with facebook
share via e-mail
02/28/2014 | 05:03pm CEST

DUBLIN, Feb. 28, 2014 /PRNewswire/ --

    --  Accretive transaction accelerates Endo's transformation into a leading
        specialty healthcare company
    --  Creates a compelling financial and operational platform for future
    --  Establishes Endo's global pharmaceuticals footprint
    --  Endo Health Solutions Inc. becomes Endo International plc

Endo International plc (Nasdaq: ENDP; TSX: ENL), formerly Endo Health Solutions Inc., announced today that it has completed the acquisition of Paladin Labs Inc. in a stock and cash transaction currently valued at approximately $2.7 billion. The acquisition accelerates Endo's strategic transformation into a leading global specialty healthcare company and creates a platform for future growth in North America and around the globe.

In connection with the acquisition, Endo and Paladin Labs have been combined under a new company incorporated in Ireland named Endo International plc. Shares of Endo International plc will trade on NASDAQ under the ticker symbol ENDP and the Toronto Stock Exchange under the ticker symbol ENL.

Under the terms of the transaction, Paladin Labs shareholders received 1.6331 shares of Endo International plc stock and $1.16 (CAD) in cash for each Paladin Labs share they owned upon closing. In addition, for each Paladin Labs share owned at closing, shareholders of Paladin Labs received one share of Knight Therapeutics Inc., ("Knight Therapeutics") a newly formed Canadian company that has been separated as part of the transaction. Shareholders of Endo Health Solutions received one share of Endo International plc for each share of Endo Health Solutions Inc. they owned upon closing.

"The combination of Endo and Paladin Labs accelerates Endo's transformation into a leading global specialty healthcare company and establishes a platform for additional strategic acquisitions," said Rajiv De Silva, president and chief executive officer of Endo. "Endo will continue with a sharp strategic focus, lean operating model and improved execution of core businesses. Strategic acquisitions will also continue to play a key role in maximizing our growth potential and creating value for Endo International shareholders."

About Endo

Endo International plc is a global specialty healthcare company focused on improving patients' lives while creating shareholder value. Endo develops, manufactures, markets, and distributes quality branded pharmaceutical, generic and device products through its operating companies. Endo has global headquarters in Dublin, Ireland and US headquarters in Malvern, PA. Learn more at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE Endo International plc

share with twitter share with LinkedIn share with facebook
share via e-mail
05/24 ENDO INTERNATIONAL PLC : Today's Research Reports on Stocks to Watch: Endo Inter..
05/10 ENDO INTERNATIONAL PLC : Today's Research Reports on Stocks to Watch: Endo Inter..
05/09 ENDO INTERNATIONAL PLC : Investor Network: Endo International Plc to Host Earnin..
05/03DJPerrigo Says Investigators Searched Its Offices in Generic-Drug Probe
02/08 Canada's TMX seeks part of Saudi Aramco listing
01/24 U.S. reaches settlement with Endo on pay-for-delay charges
01/12 ENDO INTERNATIONAL PLC : Biotech and Healthcare Stocks Hit Hard by President Tru..
01/04 ENDO INTERNATIONAL PLC : Bronstein, Gewirtz & Grossman, LLC Reminds Investors of..
2016 U.S. stock market performance in 2016
2016 ENDO INTERNATIONAL PLC : Bronstein, Gewirtz & Grossman, LLC Reminds Investors of..
More news
Sector news : Generic Pharmaceuticals
02:43pDJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Generic Pharmaceuticals
Financials ($)
Sales 2017 3 529 M
EBIT 2017 1 429 M
Net income 2017 -60,7 M
Debt 2017 5 045 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 12,31
EV / Sales 2017 2,24x
EV / Sales 2018 2,25x
Capitalization 2 876 M
More Financials
Technical analysis trends ENDO HEALTH SOLUT...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 15,9 $
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Paul V. Campanelli President, Chief Executive Officer & Director
Roger H. Kimmel Chairman
Terrance J. Coughlin Chief Operating Officer & Executive Vice President
Blaise Coleman Chief Financial Officer & Executive Vice President
Robert J. Cobuzzi SVP-Operations, Research & Development Strategy
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
More Results